Real-World Community Practice Experience With Luspatercept Following Erythropoiesis-Stimulating Agent Failure in Patients With Lower-Risk Myelodysplastic Syndromes

FEATURING:

Guillermo Garcia-Manero, MD
Professor, Department of Leukemia, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, characterizes the clinical outcome improvements observed with luspatercept for lower-risk myelodysplastic syndromes in clinical practice.